StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) stock

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1382.75−32.80 (-2.32%)

Close on Nov 18, 2026Market cap $1.30TP/E 44.9Yield 0.45%

Eli Lilly revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Eli Lilly's revenue for the twelve months ending Sep 30, 2026 was $86.46B, up 45.5% year over year. For fiscal 2025 it was $65.18B, up 44.7% from the year before. Over ten years it grew 12.6% a year on average. The highest annual figure on record is $65.18B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$65.18B+44.7%
FY2024Dec 31, 2024$45.04B+32.0%
FY2023Dec 31, 2023$34.12B+19.6%
FY2022Dec 31, 2022$28.54B+0.8%
FY2021Dec 31, 2021$28.32B+15.4%
FY2020Dec 31, 2020$24.54B+9.9%
FY2019Dec 31, 2019$22.32B+3.8%
FY2018Dec 31, 2018$21.49B+7.6%
FY2017Dec 31, 2017$19.97B-5.9%
FY2016Dec 31, 2016$21.22B+6.3%
FY2015Dec 31, 2015$19.96B+1.7%
FY2014Dec 31, 2014$19.62B-15.1%
FY2013Dec 31, 2013$23.11B+2.3%
FY2012Dec 31, 2012$22.60B-6.9%
FY2011Dec 31, 2011$24.29B+5.2%
FY2010Dec 31, 2010$23.08B+5.7%
FY2009Dec 31, 2009$21.84B+7.2%
FY2008Dec 31, 2008$20.37B+9.3%
FY2007Dec 31, 2007$18.63B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$24.40B+38.6%
Q2 FY2026Jun 30, 2026$22.97B+47.7%
Q1 FY2026Mar 31, 2026$19.80B+55.5%
Q4 FY2025Dec 31, 2025$19.29B+42.6%
Q3 FY2025Sep 30, 2025$17.60B+53.9%
Q2 FY2025Jun 30, 2025$15.56B+37.6%
Q1 FY2025Mar 31, 2025$12.73B+45.2%
Q4 FY2024Dec 31, 2024$13.53B+44.7%
Q3 FY2024Sep 30, 2024$11.44B+20.4%
Q2 FY2024Jun 30, 2024$11.30B+36.0%
Q1 FY2024Mar 31, 2024$8.77B+26.0%
Q4 FY2023Dec 31, 2023$9.35B+28.1%
Q3 FY2023Sep 30, 2023$9.50B+36.8%
Q2 FY2023Jun 30, 2023$8.31B+28.1%
Q1 FY2023Mar 31, 2023$6.96B-10.9%
Q4 FY2022Dec 31, 2022$7.30B-8.7%
Q3 FY2022Sep 30, 2022$6.94B+2.5%
Q2 FY2022Jun 30, 2022$6.49B-3.7%
Q1 FY2022Mar 31, 2022$7.81B+14.8%
Q4 FY2021Dec 31, 2021$8.00B+7.5%
Q3 FY2021Sep 30, 2021$6.77B+18.0%
Q2 FY2021Jun 30, 2021$6.74B+22.6%
Q1 FY2021Mar 31, 2021$6.81B+16.1%
Q4 FY2020Dec 31, 2020$7.44B+21.7%
Q3 FY2020Sep 30, 2020$5.74B+4.8%
Q2 FY2020Jun 30, 2020$5.50B-2.4%
Q1 FY2020Mar 31, 2020$5.86B+15.1%
Q4 FY2019Dec 31, 2019$6.11B+8.5%
Q3 FY2019Sep 30, 2019$5.48B+3.2%
Q2 FY2019Jun 30, 2019$5.64B+0.9%
Q1 FY2019Mar 31, 2019$5.09B+2.6%
Q4 FY2018Dec 31, 2018$5.64B-8.5%
Q3 FY2018Sep 30, 2018$5.31B-6.2%
Q2 FY2018Jun 30, 2018$5.59B-4.1%
Q1 FY2018Mar 31, 2018$4.96B-5.1%
Q4 FY2017Dec 31, 2017$6.16B+6.9%
Q3 FY2017Sep 30, 2017$5.66B–
Q2 FY2017Jun 30, 2017$5.82B–
Q1 FY2017Mar 31, 2017$5.23B–
Q4 FY2016Dec 31, 2016$5.76B–

More Eli Lilly figures

See a number that looks wrong?